Patents by Inventor Martin Opper

Martin Opper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in
    Patent number: 7314753
    Abstract: The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: January 1, 2008
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Martin Opper, Klaus Bosslet, Joerg Czech
  • Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli
    Publication number: 20050100984
    Abstract: The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
    Type: Application
    Filed: August 4, 2003
    Publication date: May 12, 2005
    Inventors: Martin Opper, Klaus Bosslet, Joerg Clech
  • Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli
    Patent number: 6602688
    Abstract: The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
    Type: Grant
    Filed: March 22, 1999
    Date of Patent: August 5, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Martin Opper, Klaus Bosslet, Joerg Czech
  • Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli
    Patent number: 6008023
    Abstract: The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
    Type: Grant
    Filed: April 10, 1996
    Date of Patent: December 28, 1999
    Assignee: Hoechst Marion Roussel Deutschland GmbH
    Inventors: Martin Opper, Klaus Bosslet, Joerg Czech